Get the Stockscreener App
246.88
2.13%
-5.38
Pre-market:
246.88
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $246.88, with a volume of 2.57M.
It is down -2.13% in the last 24 hours and down -9.81% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$252.26
Open:
$254.51
24h Volume:
2.57M
Relative Volume:
2.51
Market Cap:
$36.15B
Revenue:
$5.15B
Net Income/Loss:
$1.40B
P/E Ratio:
25.96
EPS:
9.5082
Net Cash Flow:
$1.65B
1W Performance:
-4.86%
1M Performance:
-9.81%
6M Performance:
+4.35%
1Y Performance:
+1.82%
1-Day Range:
$239.41
$257.17
1-Week Range:
$239.41
$264.00
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
246.88 | 36.82B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ISRG
Intuitive Surgical Inc
|
534.28 | 187.89B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
178.71 | 51.42B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
73.89 | 36.71B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
282.07 | 20.04B | 2.96B | 487.70M | 344.00M | 6.6758 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Harel Insurance Investments & Financial Services Ltd. Raises Holdings in ResMed Inc. $RMD - MarketBeat
W.G. Shaheen & Associates DBA Whitney & Co Increases Stock Position in ResMed Inc. $RMD - MarketBeat
Hantz Financial Services Inc. Has $307,000 Stock Holdings in ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock see valuation expansionPortfolio Update Summary & Free Fast Gain Swing Trade Alerts - newser.com
William Blair Has Pessimistic Outlook of ResMed Q2 Earnings - MarketBeat
Can swing trading help recover from ResMed Inc. lossesMarket Activity Summary & Daily Technical Stock Forecast Reports - newser.com
Will ResMed Inc. outperform the market2025 Major Catalysts & Safe Capital Growth Trade Ideas - newser.com
Is ResMed Inc. (RME) stock a buy on weaknessJuly 2025 Sentiment & Free Risk Controlled Daily Trade Plans - newser.com
ResMed: Q1 result 2026 - intelligentinvestor.com.au
ResMed Inc. Files Quarterly Report, Affirms Market Position - TipRanks
How supply shortages influence ResMed Inc. (Common Stock) (RMEA) stockM&A Rumor & Consistent Growth Stock Picks - newser.com
Is ResMed Inc. stock oversold or undervaluedJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Why ResMed Inc. stock benefits from AI revolutionTrade Risk Summary & Weekly High Return Stock Opportunities - newser.com
Will ResMed Inc. stock benefit from mergersRecession Risk & Target Return Focused Picks - newser.com
Is ResMed Inc. stock vulnerable to regulatory risks2025 Trade Ideas & Real-Time Chart Breakout Alerts - newser.com
Why ResMed Inc. (RME) stock remains stable2025 Performance Recap & AI Forecast Swing Trade Picks - newser.com
Pinnacle Associates Ltd. Sells 3,354 Shares of ResMed Inc. $RMD - MarketBeat
Spire Wealth Management Increases Stake in ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. stock deliver consistent dividends2025 Earnings Surprises & Stepwise Trade Signal Guides - newser.com
Oppenheimer Asset Management Inc. Cuts Stock Position in ResMed Inc. $RMD - MarketBeat
Bessemer Group Inc. Has $838,000 Stock Position in ResMed Inc. $RMD - MarketBeat
Published on: 2025-11-02 03:04:22 - newser.com
Will ResMed Inc. (RME) stock profit from automation waveWeekly Trade Review & Expert Verified Stock Movement Alerts - newser.com
ResMed, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Is ResMed Inc. reversing from oversold territoryPortfolio Risk Report & Reliable Entry Point Trade Alerts - newser.com
How ResMed Inc. (Common Stock) (RMEA) stock reacts to fiscal policies2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - newser.com
ResMed (RMD) Margin Beat Reinforces Quality Earnings Narrative - Sahm
ResMed (NYSE:RMD) Price Target Raised to $303.00 - MarketBeat
ResMed outlines high single-digit growth targets for mask segment as new fabric mask launches drive innovation - MSN
ResMed (NYSE:RMD) Given New $299.00 Price Target at KeyCorp - MarketBeat
ResMed Inc. (NYSE:RMD) Declares $0.60 Quarterly Dividend - MarketBeat
ResMed Inc. (NYSE:RMD) Q1 2026 Earnings Call Transcript - Insider Monkey
ResMed (NYSE:RMD) Price Target Cut to $300.00 by Analysts at Mizuho - MarketBeat
Can ResMed Inc. stock sustain revenue momentumEarnings Growth Report & Weekly Breakout Stock Alerts - newser.com
What to do if you’re stuck in ResMed Inc.Gap Down & Precise Buy Zone Tips - newser.com
Keybank National Association OH Has $22.72 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Day 9 of Loss Streak for ResMed Stock with -9% Return (vs. 8.7% YTD) [10/31/2025] - Trefis
ResMed Inc. $RMD Stock Position Reduced by AlphaQuest LLC - MarketBeat
ResMed Inc. stock momentum explainedWeekly Profit Summary & Daily Volume Surge Trade Alerts - newser.com
ResMed Inc. Reports Strong Q1 Earnings Amid Growth Challenges - TipRanks
Mizuho Maintains ResMed (RMD) Outperform Recommendation - Nasdaq
ResMed (NYSE:RMD) Issues Quarterly Earnings Results - MarketBeat
Resmed’s Q1 Earnings Delivered Modest Growth And Raised Optimism - Finimize
Baird Adjusts Price Target on ResMed to $300 From $320 - MarketScreener
Jefferies & Co Adjusts ResMed Price Target to $285 From $290 - MarketScreener
Wells Fargo Adjusts ResMed Price Target to $265 From $280 - MarketScreener
Wolfe Research Adjusts ResMed Price Target to $225 From $215 - MarketScreener
Morgan Stanley Adjusts ResMed Price Target to $305 From $304 - MarketScreener
Mizuho Adjusts Price Target on ResMed to $300 From $310 - MarketScreener
Does ResMed's (RMD) Strong Q1 and Steady Dividend Reveal a Durable Growth-Margin Balance? - simplywall.st
Keybanc Analyst Raises ResMed (RMD) Price Target to $299 | RMD S - GuruFocus
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):